ISSUE 1532
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line endocrine-based therapy in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib is also available copackaged with the aromatase inhibitor letrozole (Femara, and generics) as Kisqali Femara Co-Pack. Ribociclib is the second CDK 4/6 inhibitor to be approved in the US for this indication; palbociclib (Ibrance) was the first.1 Abemaciclib (Verzenio), a third CDK 4/6 inhibitor, was recently approved and will be reviewed in a future issue.
STANDARD TREATMENT — An aromatase inhibitor, with or without the CDK 4/6 inhibitor palbociclib, is
... more- Palbociclib (Ibrance) for metastatic breast cancer. Med Lett Drugs Ther 2015; 57:115.
- HS Rugo et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 2016; 34:3069.
- CG Murphy and MN Dickler. The role of CDK 4/6 inhibition in breast cancer. Oncologist 2015; 20:483.
- GN Hortobagyi et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375:1738.
- Inhibitors and inducers of CYP enzymes and p-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed October 12, 2017.
- RL Woosley and KA Romero. QT drugs list. Available at www. crediblemeds.org. Accessed October 12, 2017.

Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1532d
Electronic, downloadable article - $45